Earnings HQ: FBN’s Adam Shapiro breaks down Eli Lilly ’s fourth-quarter earnings report.
Eli Lilly CEO John Lechleiter discusses his outlook for growth and when he expects to have patent expirations behind.
Earnings HQ: FBN’s Lori Rothman breaks down Eli Lilly ’s third-quarter earnings report.
Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.
Earnings HQ: FBN’s Ashley Webster breaks down Eli Lilly ’s second-quarter earnings report.
Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.
Eli Lilly CEO John Lechleiter on where we are in the fight for cancer.
Eli Lilly CEO John Lechleiter gives his outlook for growth and new products.
Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.
Schulte, Roth & Zabel managing partner Paul Roth weighs in on the U.S. corporate tax rate.
Rehmann Financial Principal Joe Heider on the health-care stocks to watch.
Alkeus Pharmaceuticals CEO Leonide Saad on the company’s research.
Citigroup Institutional Clients Group vice Chairman Leon Kalvaria gives his outlook for the M&A market.
Claman on Call: FBN’s Liz Claman with an after-hours web exclusive on the markets and Amazon and Google’s fourth-quarter results.
The Edge COO Ryan Mendy discusses how to find activist-magnet stocks.
Christ Church Cathedral’s Rev. Stephen Carlsen on the lawsuit against JPMorgan claiming the bank mismanaged millions of dollars of the church’s money.
Eli Lilly CEO John Lechleiter discusses new products, 2015 outlook, its Alzheimer’s disease program and animal health division.
FBN’s Jo Ling Kent, Maria Bartiromo and Liz MacDonald discuss the big stories of the day and bid farewell to stage manager Benny Almonte.
David Benoit and Liz Hoffman of The Wall Street Journal on activist investor Bill Ackman’s new stake in animal health company Zoetis.
Chase Bank Chief Economist Anthony Chan says even though corrections occur investors should focus on improving fundamentals.